Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Revolutionizing the Approach to Spine Surgery We are more than a medical technolo...
Revolutionizing the Approach to Spine Surgery ...
DURECT is a biopharmaceutical company actively developing therapeutics based on it...
DURECT is a biopharmaceutical company actively ...
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
IDEXX Laboratories, Inc. is a member of the S&P 500ÂŽ Index and is a leader in pet...
IDEXX Laboratories, Inc. is a member of the S&P...
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Join the National Investor Network and get the latest information with your interests in mind.